Compare CRGO & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRGO | SERA |
|---|---|---|
| Founded | 2012 | 2008 |
| Country | Spain | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.7M | 75.2M |
| IPO Year | 2022 | 2021 |
| Metric | CRGO | SERA |
|---|---|---|
| Price | $1.19 | $2.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.40 | N/A |
| AVG Volume (30 Days) | ★ 246.3K | 21.1K |
| Earning Date | 05-26-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,000.00 |
| Revenue This Year | $10.61 | $554.81 |
| Revenue Next Year | $16.85 | $517.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 5.19 |
| 52 Week Low | $1.14 | $1.56 |
| 52 Week High | $4.24 | $3.95 |
| Indicator | CRGO | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 41.69 | 50.14 |
| Support Level | $1.17 | $1.79 |
| Resistance Level | $1.43 | $2.07 |
| Average True Range (ATR) | 0.09 | 0.10 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 3.45 | 33.15 |
Freightos Ltd operates as a vendor-neutral booking and payment platform for international freight. Its platform supports supply chain efficiency and agility by enabling real-time procurement of ocean and air shipping across more than ten thousand importers/exporters, thousands of forwarders, and dozens of airlines and ocean carriers. The company operates in two segments: the Platform segment and the Solutions segment. The majority of the revenue is derived from the Solutions segment, which provides software tools and data to help industry participants automate their pricing, sales, and procurement processes. Geographically, it generates the maximum revenue from Europe, and the rest from the United States, Hong Kong and Others.
Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.